AUA 2019: PSMA-PET in High-Risk nmCRP... - Advanced Prostate...

Advanced Prostate Cancer

21,407 members26,790 posts

AUA 2019: PSMA-PET in High-Risk nmCRPC SPARTAN-Like Patients Negative by Conventional Imaging.

tango65 profile image
2 Replies

"In the PSMA-PET group, PSMA-PET CT detected PC in 196/200 (98%) pts! 55% had local recurrence, 54% had pelvic nodes (N1), and 55% had any extrapelvic distant metastatic disease despite negative conventional imaging. Ultimately, 24% were diagnosed with local recurrence only, 29% with oligometastatic (1-3 lesions) and 46% with polymetastatic disease. "

urotoday.com/conference-hig...

-----------------

Written by
tango65 profile image
tango65
To view profiles and participate in discussions please or .
2 Replies
Tall_Allen profile image
Tall_Allen

This is not at all surprising, but it may be a mistake to get a PSMA-based PET scan for men with nmCRPC because insurance may not want to cover Erleada once mets have been detected, and there is no known benefit for met-directed therapy.

bobdc6 profile image
bobdc6

" Patients with isolated, painful bone lesions may be treated with palliative external beam radiation. Additionally, oligometastatic disease may be treated to slow progression."

ncbi.nlm.nih.gov/pmc/articl...

You may also like...

Failed RP & SRT; Negative PSMA PET

have failed as well. A recent PSMA PET scan showed no signs of recurrent prostate cancer or...

Best alternative PET for PSMA negative PCa

now rising (3+) but PSMA-PET was negative, even in the prostate - implying PSMA non-avid cancer....

Advanced recurrent PCa, rising PSA, 2 negative PSMA PET Scans

the new FDA approved Pyl 18F PSMA PET scan. It also came back negative. So, we then scheduled a 3T

MRI negative findings contradict PSMA PET/CT finding of likely disease recurrence within prostate.

to 1.0 in 7 months, suspicion for recurrence. Did a Pylarify PSMA PT/CT that found hot spots...

FDA Approves another PSMA PET scan for Prostate Cancer Imaging

aging Like the other two PSMA PET scans, it is approved for both recurrent patients and high risk...